Optometry Insight Report
Optometrist perspectives on smart contact lenses, continuous data, drug delivery, corneal safety, reimbursement and clinical ownership.
Audience: Optometrists
Countries: 3
Survey records: 23
-Hero findings
– Quick Read — Key Findings
The full report explores how optometrists are thinking about clinical ownership, continuous IOP data, drug delivery, corneal safety, Big Tech, reimbursement and workflow design.
Drug-eluting contact lenses are already a regulatory reality in a limited indication, while investigational smart lenses are being studied for continuous intraocular-pressure monitoring and feedback-guided therapy. The technology trajectory is moving from passive correction toward sensing and treatment. The MDForLives optometry responses suggest adoption will depend less on novelty alone and more on workflow ownership, corneal safety, clinical credibility and reimbursement.
Clinical context: FDA approved a ketotifen drug-eluting daily disposable contact lens in 2022, while current U.S. clinical research is evaluating sensor-enabled soft contact lenses for extended IOP monitoring in glaucoma care. These emerging devices remain indication-specific and require established contact-lens safety principles.
MDForLives captured perspectives from Optometrists across United States, Canada, Italy. The findings below focus on the operational and clinical patterns that stand out across the response data.
The core role split is almost even between primary ownership of ocular/systemic lens data and co-management with medical colleagues.
What the pattern suggests: The future role is not being framed as hardware fitting alone. Respondents expect a clinical interpretation role, but many also anticipate shared responsibility for systemic data.
Why it matters: Smart-lens adoption will need explicit ownership rules for monitoring, escalation and cross-specialty communication.
Continuous telemetry creates a new type of workload outside the appointment.
What the pattern suggests: Continuous data can turn a device into an always-on service obligation. The value of monitoring depends on how much data requires human review and how alerts are triaged.
Why it matters: A viable model needs thresholds, exception-based monitoring, reimbursement and software integration that prevent clinicians from manually watching raw data streams.
Most respondents are interested but cautious about replacing traditional drops with drug-eluting lenses.
What the pattern suggests: The technology may solve adherence, but the lens sits on a biologically sensitive surface for prolonged periods. Safety evidence therefore has to address both the drug and the device.
Why it matters: Adoption will depend on long-term ocular-surface tolerability, oxygen transmission, infection risk and the ability to stop or change therapy when needed.
The strongest clinical use signal is not the 24-hour average. It is previously unseen nocturnal IOP behaviour.
What the pattern suggests: Continuous monitoring is most persuasive when it reveals clinically relevant patterns that static tonometry cannot capture.
Why it matters: The practical question is whether new data changes management, not simply whether it can be measured.
Respondents expect tech-forward consumers to drive early financial adoption more than chronic-disease need.
What the pattern suggests: The earliest commercial pathway may look more like premium consumer wearables than reimbursed medical monitoring.
Why it matters: Optometrists may become the clinical checkpoint between consumer technology adoption and safe ocular use.
High price is the leading predicted payer barrier, while manufacturer clinical credibility is the most selected partnership factor.
What the pattern suggests: The adoption gate is partly economic and partly epistemic: clinicians need to trust the manufacturer, and payers need a credible cost-benefit case.
Why it matters: Evidence, coding, interoperability and support services will matter almost as much as the optical or sensing technology itself.
A smart lens is not only a device; it can create an ongoing monitoring workload outside the appointment.
More data matters only when it reveals a pattern that changes management.
Corneal tolerability, reimbursement and manufacturer credibility can slow adoption even when sensing technology works.
The pattern is cautious curiosity. Optometrists are already thinking past the hardware: who monitors the data, what findings are actionable, how corneal safety is protected and who pays for the time. That is the real transition from wearable novelty to clinical infrastructure.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
